Avner Geva is the Chief Executive Officer and Co-Founder of Vensica Medical, a company developing a groundbreaking drug-device combination product. Avner pioneered the technology, overseeing its evolution from conceptualization to successful progression into Phase II clinical trials. He spearheaded fundraising efforts, securing a total investment of $30 million from both venture capital firms and strategic partners. Additionally, Avner orchestrated a pivotal partnership agreement with Merz Therapeutics, a pharmaceutical industry leader, to collaboratively advance the development of our product. As part of the agreement, Vensica in-licensed Xeomin, a drug generating approximately $1 billion in revenues.

Avner is also the Co-Founder of IntraGel Therapeutics, a clinical-stage company developing sustained-release intratumoral therapy. Avner serves on IntraGel's board and led its seed financing and drug development through a pilot trial and collaborations with strategics.

Avner also collaborates with VCs and has held several roles such as Entrepreneur in Residence (EIR) and biotech principal, scouting for exciting deals, overseeing due diligence, and managing deal flow. Avner received his BSc from Yale University and his MSc from the Technion, the Israeli Institute of Technology.